HARP News and Press, Harpoon Therapeutics Inc. From 11/04/21

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that two abstracts have been accepted for poster presentation at the 63rd American So...

Julie Eastland Appointed President and Chief Executive Officer Jerry McMahon, Ph.D., Resigns from Harpoon as President and Chief Executive Officer Scott Myers, Current Member of Harpoon’s Board of Directors Named Chair, Replacing Ron Hunt Who Remains on the Board ...

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that an abstract with preclinical data of its TriTAC-XR T cell engager platform has b...

Gainers: Sonoma Pharmaceuticals (NASDAQ:SNOA) +33%, Evelo Biosciences (NASDAQ:EVLO) +12%, ZIVO Bioscience (NASDAQ:ZIVO) +12%, Viridian Therapeutics (NASDAQ:VRDN) +7%, Harpoon Therapeutics (NASDAQ:HARP) +7%. Losers: Altimmune (NASDAQ:ALT) -20%, ...

Sonoma Pharmaceuticals (NASDAQ:SNOA) +70% on product launch in U.S. and Europe Planet Green (NYSE:PLAG) +30%. ZIVO Bioscience (NASDAQ:ZIVO) +20%. Frequency Electronics (NASDAQ:FEIM) +17% wins contract from the Office of Naval Research for atomic clock development AGM Group...

Harpoon Therapeutics, Inc. stock is down over 55% since it released data on its most advanced early-stage program (HPN424 for metastatic castration-resistant prostrate cancer) in June 2020. The company has a total of four early-stage programs, the most important of which is HPN217, in...

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate ...

Harpoon Therapeutics (NASDAQ:HARP): Q2 GAAP EPS of -$0.52 misses by $0.09. Revenue of $5.8M (+110.1% Y/Y) misses by $1.19M. Harpoon ended the second quarter of 2021 with $175.2M in cash, cash equivalents, and marketable securities compared to $150.0M as of December 31, 2020.  Press Relea...

Presented updated interim Phase 1/2a clinical trial data for PSMA-targeting TriTAC ® HPN424 in prostate cancer at ASCO Annual Meeting Provided clinical trial updates for three additional TriTAC programs and ProTriTAC platform SOUTH SAN FRANCISCO, Calif., A...

Shares of Harpoon Therapeutics Inc. (NASDAQ:HARP) traded at a new 52-week low today of $9.95. Approximately 159,000 shares have changed hands today, as compared to an average 30-day volume of 503,000 shares. Based on a current price of $10.24, Harpoon Therapeutics Inc. is currently 37.8%...